Clinical Trials Logo

Dyssocial Behavior clinical trials

View clinical trials related to Dyssocial Behavior.

Filter by:
  • None
  • Page 1

NCT ID: NCT04865562 Completed - Dyssocial Behavior Clinical Trials

Hormones and Decision Making

Start date: March 1, 2015
Phase: Phase 4
Study type: Interventional

An investigation of the neuropsychological processes underlying ethical decision making.

NCT ID: NCT02361177 Withdrawn - Dyssocial Behavior Clinical Trials

Role of Oxytocin in Telling and Detecting Lies

Start date: January 2016
Phase: Phase 0
Study type: Interventional

The investigators are interested in the impact of intranasal oxytocin in unethical behavior.

NCT ID: NCT00060788 Recruiting - Clinical trials for Antisocial Personality Disorder

Antisocial Behavior: Passing From Parent to Child to Grandchild

Start date: September 2001
Phase: N/A
Study type: Observational

Antisocial behavior often occurs in different generations within the same family. However, it is not known what factors contribute to this passing of antisocial behavior from parent to child to grandchild. This study is part of a project evaluating antisocial behavior in families; it focuses on the passage of such behavior from one generation to the next.

NCT ID: NCT00000388 Completed - Clinical trials for Substance-related Disorders

Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)

MTA
Start date: September 1998
Phase: Phase 4
Study type: Interventional

This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes. In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment. A child may be eligible for this study if he/she: Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).